Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply

Documenti analoghi

• Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
  di: Luis Antonio Díaz, et al.
  Pubblicazione: (2025)
• Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
  di: Xing Bai, et al.
  Pubblicazione: (2025)
• Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
  di: Federica Tavaglione, et al.
  Pubblicazione: (2025)
• Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
  di: Maral Amangurbanova, et al.
  Pubblicazione: (2024)
• Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
  di: Francisco Idalsoaga, et al.
  Pubblicazione: (2025)